Top-rated drug stocks Jazz Pharmaceuticals, United Therapeutics and Questcor Pharmaceuticals all missed fourth-quarter sales estimates Tuesday, sending their shares down significantly. Jazz (JAZZ) reported revenue of $236 million, up 28% from a year earlier but about $2 million below analysts’ consensus. Profit minus one-time items also came up short at $1.72 a share, 6 cents below estimates but up 12% from the prior year. CFO
SolarCity spooked investors late Monday, delaying its full Q4 earnings report until March 3, though the solar installer’s revenue did beat Wall Street expectations. The company said the delay stems from accounting related to recent acquisitions “as well as a change in overhead allocation owing to an increase in the volume of MW (megawatts) deployed.” It also said it expects to install 78 to 82 MW in Q1, up 74% year over year but
The hot market for cybersecurity protection propelled Palo Alto Networks stock to an all-time high Monday, after the company’s Q2 earnings and Q3 revenue guidance beat analyst views. Revenue rose 46% from the year-earlier quarter to $141.1 million. Earnings per share, minus items, for the quarter ended Jan. 31 doubled to 10 cents, edging analyst consensus by a penny. “They’re in a really good space and growing at three to four